M
Marc A. Pfeffer
Researcher at Brigham and Women's Hospital
Publications - 815
Citations - 143710
Marc A. Pfeffer is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Heart failure & Myocardial infarction. The author has an hindex of 166, co-authored 765 publications receiving 133043 citations. Previous affiliations of Marc A. Pfeffer include Partners HealthCare & University of Miami.
Papers
More filters
Journal ArticleDOI
Sphygmomanometrically Determined Pulse Pressure Is a Powerful Independent Predictor of Recurrent Events After Myocardial Infarction in Patients With Impaired Left Ventricular Function
Gary F. Mitchell,Lemuel A. Moyé,Eugene Braunwald,Jean L. Rouleau,Victoria Bernstein,Edward M. Geltman,Greg C. Flaker,Marc A. Pfeffer +7 more
TL;DR: These data provide strong evidence for a link between pulse pressure, which is related to conduit vessel stiffness, and subsequent cardiovascular events after myocardial infarction in patients with left ventricular dysfunction.
Journal ArticleDOI
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction : Results from the candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM) program
Lars G. Olsson,Karl Swedberg,Anique Ducharme,Christopher B. Granger,Eric L. Michelson,John J.V. McMurray,Margareta Puu,Salim Yusuf,Marc A. Pfeffer,Charm Investigators +9 more
TL;DR: The risk of adverse cardiovascular (CV) outcomes associated with atrial fibrillation (AF) in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program, which enrolled patients with chronic heart failure (CHF) and a broad range of ejection fractions (EFs) was assessed as mentioned in this paper.
Journal ArticleDOI
Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial.
Martin St. John Sutton,Marc A. Pfeffer,Lemuel A. Moyé,Ted Plappert,Jean L. Rouleau,Gervasio A. Lamas,Jacques R. Rouleau,John O. Parker,Malcolm Arnold,Bruce Sussex,Eugene Braunwald +10 more
TL;DR: LV dilatation is progressive, associated with chamber distortion and deteriorating function that is unaffected by captopril beyond 1 year, and occurred in >50% of patients by 2 years.
Journal ArticleDOI
VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial
Frank M. Sacks,Petar Alaupovic,Lemuel A. Moyé,Thomas G. Cole,Bruce Sussex,Meir J. Stampfer,Marc A. Pfeffer,Eugene Braunwald +7 more
TL;DR: The plasma concentrations of V LDL particles and apoCIII in VLDL and LDL are more specific measures of coronary heart disease risk than plasma triglycerides perhaps because their known metabolic properties link them more closely to atherosclerosis.
Journal ArticleDOI
Red Blood Cell Distribution Width and Mortality Risk in a Community-Based Prospective Cohort
TL;DR: Higher RDW is associated with increased mortality risk in this large, community-based sample, an association not specific to CVD.